UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1293-8
Program Prior Authorization/Notification
Medication *Skyrizi® (risankizumab-rzaa) injection
*This program applies to the subcutaneous formulations of Skyrizi
P&T Approval Date 9/2019, 9/2020, 9/2021, 3/2022, 8/2022, 7/2023, 5/2024, 7/2024
Effective Date 10/1/2024
1. Background:
Skyrizi is an interleukin-23 antagonist indicated for the treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic therapy or phototherapy, active psoriatic
arthritis in adults, moderately to severely active Crohn's disease in adults, and moderately to
severely active ulcerative colitis in adults.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Diagnosis of moderate to severe plaque psoriasis
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),
Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),
© 2024 UnitedHealthcare Services, Inc.
1
Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
1. Initial Authorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Diagnosis of active psoriatic arthritis
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Stelara (ustekinumab),
Tremfya (guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
Authorization will be issued for 12 months.
C. Crohn’s Disease (CD)
1. Initial Authorization for Maintenance Dosing
a. Skyrizi will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
© 2024 UnitedHealthcare Services, Inc.
2
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, Xeljanz (tofacitinib),
Olumiant (baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab)]
Authorization will be issued for 12 months.
D. Ulcerative Colitis (UC)
1. Initial Authorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]
Authorization will be issued for 12 months.
2. Reauthorization
a. Skyrizi will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Skyrizi therapy
-AND-
(2) Patient is not receiving Skyrizi in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
© 2024 UnitedHealthcare Services, Inc.
3
(golimumab), Orencia (abatacept), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Stelara (ustekinumab), adalimumab]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits, Medical Necessity, and/or Step Therapy may be in place.
4. References:
1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; June 2024.
Program Prior Authorization/Notification – Skyrizi® (risankizumab-rzaa)
Change Control
9/2019 New program
9/2020 Annual review. Changed reauthorization duration to 12 months.
Updated reference.
9/2021 Annual review with no changes to coverage criteria. Updated
reference.
3/2022 Clinical coverage criteria updated to add active psoriatic arthritis.
Updated reference.
8/2022 Clinical coverage criteria and background updated to add Crohn’s
disease. Added state mandate footnote. Added Rinvoq as Janus kinase
inhibitor example. Updated reference.
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
5/2024 Annual review with no changes to coverage criteria. Updated reference.
7/2024 Updated clinical coverage criteria and background to add ulcerative
colitis. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
4